Clinical Trials Detalhe
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
General Information
Gender
ALL
Age
N/A
Phase
PHASE3
Study Type
INTERVENTIONAL
Location
AIBILI - Association for Innovation and Biomedical Research on Light (Coimbra, Portugal)
Espaco Medico Coimbra (Coimbra, Portugal)
Hospital de Santa Maria; Servico de Oftalmologia (Lisbon, Portugal)
Hospital de Sao Joao; Servico de Oftalmologia (Porto, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT02247531Summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Conditions
Geographic Atrophy
Eligibility
Inclusion Criteria: * Participants aged greater than or equal to (\>/=) 50 years * Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with no evidence of prior or active choroidal neovascularization (CNV) in both eyes Exclusion Criteria: Ocular Exclusion Criteria (Study Eye): * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD * Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and proliferative diabetic retinopathy * Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection, anti-angiogenic drugs, anti-complement agents, or device implantation) Ocular Exclusion Criteria (Both Eyes): * GA in either eye due to causes other than AMD * Previous treatment with eculizumab, lampalizumab, and/or fenretinide